Top 10 articles of last week
A 'breakthrough' product trial that could put biotech CSL on the path to $250 a share topped Morningstar's top 10 stories this week alongside news of another strong half-year for the Australian ETF industry.
A 'breakthrough' product trial that could put biotech CSL on the path to $250 a share topped Morningstar's top 10 stories this week alongside news of another strong half-year for the Australian ETF industry.
This ASX-listed biotech is working on a "blockbuster" cardiovascular product that has the potential to take its stock price to $250, says Morningstar equity analyst Chris Kallos.
It's been another strong half year for the Australian exchange-traded funds industry, finishing the first half of 2018 at record highs, according to the BetaShares 2018 Australian ETF Review.
This Australian financial services company may be expensive at its current price but it has a solid reputation, good profit margins and significant competitive advantages, according to Morningstar analysis.
Australians are underestimating by up to 20 per cent the amount of money they’ll need in retirement, according to a new survey from global investment manager Schroders.
The float of Viva Energy is a high-octane opportunity despite the threat of electric vehicles and increased competition, Morningstar says.
Australian super funds are closing in on a decade of positive returns as the median growth fund ends the year up by 9.2 per cent, according to a report by superannuation research house Chant West.
When it comes to diversification, the 11 million Australians holding investments outside of their superannuation fund still tend to place all their eggs in one basket.
Being aware of individual behavioural biases is a vital part of the investment process, according to Daniel Kahneman, Nobel laureate and author of Thinking, Fast and Slow.
Morningstar analysts have maintained their fair value estimate for global hospital group Ramsay Health Care (ASX: RHC) after its French subsidiary made an unsuccessful bid to acquire pan-European healthcare service provider Capio.
SMSF trustees looking to invest their savings in the property market have suffered another blow following the move by the nation's second largest mortgage lender to withdraw new loan offers.
More from Morningstar
• Make better investment decisions with Morningstar Premium | Free 4-week trial
Lex Hall is a Morningstar content editor, based in Sydney.
© 2018 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/s/fsg.pdf. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782 ("ASXO"). The article is current as at date of publication.
